Treatment of multiple sclerosis
The first disease-modifying therapy for relapsing–remitting multiple sclerosis — interferon‑β 1b — was approved by the FDA in 1993. The following 25 years have seen rapid expansion of the therapeutic options as an evolving understanding of the disease has enabled development of therapies with different modes of action. As a result, we now have a complex treatment landscape that includes various injectables, oral drugs and monoclonal antibodies, each of which has its own advantages and risks. This Milestone tracks the development of the treatment of multiple sclerosis on an interactive Timeline, from the approval of the first disease-modifying therapy to the latest breakthroughs that have seen unprecedented efficacy and approval of the first drug for primary progressive multiple sclerosis.
This Milestone is editorially independent, produced with financial support from a third party. About this content.
Nature Research is pleased to acknowledge financial support of Biogen and F. Hoffmann-La Roche in producing this Nature Milestone. The sponsor retains sole responsibility for the following messages.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube. Please read the sponsor's article
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare.
Roche is the world’s largest biotech company, with differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines1, among them life-saving antibiotics, antimalarials and cancer medicines.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide2. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com
